MedTrace Logo

Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients

NCT03910426 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 216

Last updated 2023-05-03

No results posted yet for this study

Summary

Patients with end-stage kidney disease are treated with dialysis to increase their life expectancy as well as their quality of life (QoL). Scientific researchers are currently still looking for markers to evaluate dialysis in an objective way. It has been proven before that the currently clinically used parameters (like the dialysis adequacy parameter Kt/V) are not appropriate enough to estimate dialysis dose.

The current project aims at identifying potential (predicting) biomarkers based on functional capacity, nutritional status and/or QoL.

Conditions

  • Dialysis
  • Quality of Life
  • Nutrition

Interventions

OTHER

Blood sampling

Blood is sampled before a midweek dialysis session once every year with a maximum of 3 samples in total.

OTHER

Nails collection

At the occasion of the blood sampling, finger nails are cut and collected.

OTHER

Stool collection

At the occasion of the blood sampling, patients are asked to bring a stool sample.

OTHER

Physical Functioning

A subgroup of patients are asked to perform some physical tests.

OTHER

Sleep

A subgroup of patients are asked to sleep 2-3 nights with a Motionwatch (Actigraphy) to recording their arm movements.

Sponsors & Collaborators

  • University Hospital, Antwerp

    collaborator OTHER

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Wim Van Biesen, PhD, MD · University Hospital, Ghent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-15
Primary Completion
2018-12-31
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03910426 on ClinicalTrials.gov